CSF-1 Overexpression Predicts Poor Prognosis in Upper Tract Urothelial Carcinomas
Table 1
Correlation of CSF-1 expression with clinicopathological characteristics in upper tract urothelial carcinomas.
Variables
Item
Patient no. (%)
CSF-1
value
Low
High
No.
%
No.
%
Total
112 (100)
58
51.8
54
48.2
Stage
I/II
73 (65.2)
47
81.0
26
48.1
<0.001a
III/IV
39 (34.8)
11
19.0
28
51.9
Grade
Low
30 (26.8)
17
29.3
13
24.1
0.532a
High
82 (73.2)
41
70.7
41
75.9
Gender
Female
68 (60.7)
37
63.8
31
57.4
0.489a
Male
44 (39.3)
21
36.2
23
42.6
Age (years)
<65
42 (37.5)
17
29.3
25
46.3
0.068a
≥65
70 (62.5)
41
70.7
29
53.7
Tumor location
Ureter
47 (42.0)
25
43.1
22
40.7
0.300a
Renal pelvis
45 (40.2)
20
34.5
25
46.3
Renal pelvis+ureter
20 (17.9)
13
22.4
7
13.0
Tumor sidec
Right
49 (44.5)
25
44.6
24
44.4
0.983a
Left
61 (55.5)
31
55.4
30
55.6
Lymphovascular invasion
Negative
89 (79.5)
48
82.8
41
75.9
0.371a
Positive
23 (20.5)
10
17.2
13
24.1
Distant metastasis
Negative
96 (85.7)
55
94.8
41
75.9
0.006b
Positive
16 (14.3)
3
5.2
13
24.1
Recurrence
Negative
62 (55.4)
40
69.0
22
40.7
0.003a
Positive
50 (44.6)
18
31.0
32
59.3
Cancer death
No
93 (83.0)
54
93.1
39
72.2
0.005b
Yes
19 (17.0)
4
6.9
15
27.8
Creatinine (mg/dl)
≤1.5
66 (58.9)
35
60.3
31
57.4
0.752a
>1.5
46 (41.1)
23
39.7
23
42.6
aThe value was calculated by the chi-square test. bThe value was calculated by the Fisher’s exact test. cTumor side was not determined in a small portion of the patients.